Dr. Igor Fisch to Present Data on Using Genome Engineering and the Selexis SURE CHO-Mplus Libraries for Optimal Transgene Expression and Recombinant Protein Production
Geneva, Switzerland, May 30, 2014 – Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today the Company’sCEO, Igor Fisch, PhD, will present “Genome Engineering and SURE CHO-Mplus Libraries™ for Optimal Transgene Expression andRecombinant Protein Production” at the BioProcess Theater on June 24, 2014 at 2:30 PM. The BioProcess Theater presentations are part of the BIO International Convention being held Jun 23-26 in San Diego, California at the San Diego Convention Center.
Presentation Abstract:
Based on proprietary epigenetic DNA regulator elements and leveraging the SURE CHO-M Genome and Transcriptome, Selexis has developed a novel platform approach for the generation of CHO cell lines. By combining robust transcription with a library approach to debottlenecking translation, folding and secretion, Selexis has launched the SURE CHOM-Mplus™ Libraries. This technology has an extensive history of generating high-level, stable expressing cell lines, including cell lines producing difficult-to-express proteins such as Fc-fusions and large multimeric proteins. The extensive characterization of the CHO-M cell line supports comprehensive and effective transfer packages for manufacturing.
Igor Fisch, PhD, CEO of Selexis
"This technology has an extensive history of generating high-level, stable expressing cell lines, including cell lines producing difficult-to- express proteins such as Fc-fusions and large multimeric proteins."
